ClinicalTrials.gg
CompletedNCT01480284Updated Aug 10, 2016Results posted

Phase 3 Study of GSK548470 in Patients With Compensated Chronic Hepatitis B Untreated With Nucleic Acid Analogue

A Phase 3 interventional study of GSK548470 300 mg tablet and ETV 0.5 mg capsule in Hepatitis B, Chronic, sponsored by GlaxoSmithKline. Completed at 32 sites in Japan. Open to participants aged 16 Years to 69 Years. Per ClinicalTrials.gov, last updated 2016-08-10.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
166
Allocation
Randomized
Ages
16 Years to 69 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 50 studies testing tenofovir in Hepatitis B, Chronic — none open to participants now, 1 under way, 1 of them phase 3. Tenofovir · Hepatitis B, Chronic.

Enrollment
17th of 50
166 · median 117
Started
2011
with 5 others
Phase 3
13 of 50
none open now
Registered
22nd of 50
by date
Lead sponsor
7 of 50
GlaxoSmithKline

Among the 50 studies testing tenofovir in Hepatitis B, Chronic, this one is the 17th largest by enrollment, is one of 6 that started in 2011, is one of 13 in phase 3, and was the 22nd registered.

Hepatitis B, Chronic

896 studies on the registry are indexed under Hepatitis B, Chronic; 153 are open to participants now.

Browse Hepatitis B, Chronic studies →

Open to participants now

None of the 50 studies testing tenofovir in Hepatitis B, Chronic is open now. The open studies under Hepatitis B, Chronic, anywhere →

About tenofovir

Tenofovir: first FDA approval 2001 (VIREAD), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 13 take healthy volunteers.

This study: 16 Years to 69 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 50 studies testing tenofovir in Hepatitis B, Chronic as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of GSK548470 administered once daily at a dose level of 300 mg to Japanese patients with compensated chronic hepatitis B untreated with any nucleic acid analogue. In efficacy, the non-inferiority of GSK548470 to ETV will be verified using the antiviral effect as the index.

Read the detailed description

This study is a multicenter, randomized, active comparator-controlled, double-blind, parallel-group comparison study in Japanese patients with compensated chronic hepatitis B untreated with any nucleic acid analogue and its subsequent open-label study. Efficacy and safety will be compared between once-daily dosing of GSK548470 300 mg and once-daily dosing of ETV 0.5 mg, and subsequently the efficacy and safety of GSK548470 administered long term will be investigated. A total of 165 subjects will be assigned to the GSK548470 group or the ETV group at a ratio of 2:1. The subjects will be assigned by stratified randomization in terms of HBe antigen and serum HBV-DNA level. The primary purpose is to verify the non-inferiority of GSK548470 to ETV using as an index the change amount of HBV-DNA level at Week 24 from the baseline level. The secondary purpose is to investigate the efficacy and safety of GSK548470 300 mg administered once daily for a long term.

03

Conditions studied

  • Hepatitis B, Chronic

Browse trials for

Keywords

  • Tenofovir Disoproxil Fumarate
  • Chronic Hepatitis B
04

Who can participate

Ages eligible
16 Years to 69 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The ability to understand and sign a written form
  • 16 to 69 years of age at the time of informed consent
  • Females of must have a negative pregnancy test and agree to avoidance of pregnancy
  • Subject must show \< 450 millisecond (msec) or \< 480 msec with Bundle Branch Block
  • Chronic infection, defined as positive serum HBsAg for at least 6 month, or negative serum IgM-HBc antibody
  • HBeAg positive; HBV-DNA >= 6 log10 copies/mL, HBeAg negative; HBV-DNA >= 5 log10 copies/mL
  • Serum >= 31 U/L and \<= 10 ×
  • >= 70 mL/min
  • >= 8 g/dL
  • WBC >= 1,000 /mm3
  • Nucleic acid analogue naïve, i.e., no prior therapy for over 6 months in the past
  • No mutation that shows resistance in LAM, ETV and/or TDF at screening

Exclusion criteria

Exclusion Criteria:

  • Decompensated liver disease
  • Co-infection with or
  • hepatitis rather than chronic
  • Subject with serious complication
  • Received or have a plan for solid organ or bone marrow transplantation
  • Has proximal tubulopathy
  • History of to nucleoside and/or nucleotide analogues
  • Evidence of hepatocellular carcinoma by diagnostic imaging at screening and/or serum α-fetoprotein > 50 ng/mL at screening
  • History of HCC
  • Received any nucleoside, nucleotide, interferon or HB vaccine therapy within 24 weeks prior to initiation
  • Received overdose NSAIDs, excluding temporary or topical use, within 7 days prior to initiation
  • Received drugs for injection containing glycyrrhizin as the main component within 4 weeks prior to initiation
  • Received drugs causing renal impairment, competitors of renal excretion, , chemotherapeutics and/or within 8 weeks prior to initiation
  • Participation in another clinical study within 6 months of study entry or planned participation in another clinical study after entry to this study
  • Woman who is pregnant, lactating, possibly pregnant or planning a pregnancy during the study period
  • Psychiatry disorder or cognitive disorder that may affect the subject ability to give or to follow specified study procedures
  • History of alcohol or drug abuse
  • Any condition or situation that may interfere with the subject's participation in the study
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
166 participants (actual)

Study arms

  • Experimental
    GSK548470 300 mg

    GSK548470 300 mg tablet and ETV placebo capsule are administered once daily

    Drug: GSK548470 300 mg tablet

  • Active comparator
    ETV 0.5 mg

    ETV 0.5 mg capsule and GSK548470 placebo tablet are administered once daily

    Drug: ETV 0.5 mg capsule

Interventions

  • Blue tablets, each tablet containing 300 mg of tenofovir disoproxil fumarate

    Also known as: GSK548470

  • Brown capsules, each capsule containing 0.53 mg of entecavir hydrate

    Also known as: ETV

06

What researchers measure

Primary outcomes

  1. Mean Change From Baseline in Serum HBV DNA Level at Week 24

    The mean change from Baseline in the hepatitis B virus deoxyribonucleic acid (HBV DNA) level at Week 24 was assessed (lower limit of quantitation : 2.1 log 10 copies/mL). The mean values were adjusted by Baseline HBV DNA levels. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

    Time frame: Baseline and Week 24

Secondary outcomes

  1. Mean Change From Baseline in Serum HBV DNA Level at Week 48 and Week 96

    The mean change from Baseline in the HBV DNA level at Week 48 and Week 96 were assessed (lower limit of quantitation : 2.1 log10 copies/mL). The mean values were adjusted by Baseline HBV DNA levels. Change from Baseline was calculated as the post-baseline value minus the Baseline value. The LOCF method was applied for missing values.

    Time frame: Baseline, Week 48 and Week 96

  2. Number of Participants With Serum HBV DNA < 2.1 log10 Copies/mL at Week 24, Week 48 and Week 96

    The number of participants with serum HBV DNA level less than the lower limit of quantitation (i.e. 2.1 log10 copies/mL) at Week 24, Week 48 and Week 96 were summarized. The LOCF method was applied for missing values.

    Time frame: Week 24, Week 48 and Week 96

  3. Number of Participants With Alanine Aminotransferase (ALT) Normalization at Week 24, Week 48 and Week 96

    The number of participants with alanine aminotransferase (ALT) normalization at Week 24, Week 48 and Week 96 were summarized. ALT normalization is defined as when an ALT value exceeds the upper limit of normal range (ULN) at Baseline and within the normal range at the end of treatment. The LOCF method was applied for missing values.

    Time frame: Week 24, Week 48 and Week 96

  4. Number of Participants With HBeAg Loss at Week 24, Week 48 and Week 96

    The number of participants achieving hepatitis Be antigen (HBeAg) loss at Week 24, Week 48 and Week 96 in positive HBeAg participants at Baseline were summarized. Loss of HBeAg is defined as the change of detectable HBeAg from positive to negative. The LOCF method was applied for missing values.

    Time frame: Week 24, Week 48 and Week 96

  5. Number of Participants With HBeAg/HBeAb Seroconversion at Week 24, Week 48 and Week 96

    The number of participants achieving HBeAg/hepatitis Be antibody (HBeAb) seroconversion at Week 24, Week 48 and Week 96 in positive HBeAg and negative HBeAb participants at Baseline were summarized. Seroconversion to HBeAg is defined as the change of detectable antibody to HBeAg from negative to positive. The LOCF method was applied for missing values.

    Time frame: Week 24, Week 48 and Week 96

  6. Number of Participants Achieving HBsAg Loss at Week 24, Week 48 and Week 96

    The number of participants with hepatitis B surface antigen (HBsAg) loss at Week 24, Week 48 and Week 96 in positive HBsAg participants at Baseline were summarized. Loss of HBsAg is defined as change of detectable HBsAg from positive to negative. The LOCF method was applied for missing values.

    Time frame: Week 24, Week 48 and Week 96

  7. Number of Participants Achieving HBsAg/HBsAb Seroconversion at Week 24, Week 48 and Week 96

    The number of participants with HBsAg/hepatitis B surface antibody (HBsAb) seroconversion at Week 24, Week 48 and Week 96 in positive HBsAg and negative HBsAb participants at Baseline were summarized. HBsAg seroconversion .is defined as change of detectable antibody to HBsAg from negative to positive. The LOCF method was applied for missing values.

    Time frame: Week 24, Week 48 and Week 96

  8. Number of Participants Achieving Each Indicated HBsAg Category at Baseline, Week 24, Week 48 and Week 96

    The number of participants achieving each indicated HBsAg category (HBsAg \<80, 80 to 800, 800 to 8000, 8000 to 80000, and \>=80000) (kilo international unit per liter \[KIU/L\]) by study visit was summarized. The LOCF method was applied for missing values.

    Time frame: Baseline, Week 24, Week 48 and Week 96

  9. Number of Participants Achieving Each Indicated HBcrAg Category at Baseline, Week 24, Week 48 and Week 96

    The number of participants achieving each indicated hepatitis B core-related antigen (HBcrAg) category (HBcrAg \<3.0, 3.0 to 4.0, 4.0 to 5.0, 5.0 to 6.0, and \>=6.0) (Log kilo unit per liter \[KU/L\]) by study visit was summarized. The LOCF method was applied for missing values.

    Time frame: Baseline, Week 24, Week 48 and Week 96

  10. Number of Participants With Virological Breakthrough Through End of the Study

    The number of participants who experienced virological breakthrough was summarized. Virological breakthrough is defined as serum HBV DNA level increase \>=1 log10 copies/mL above the treatment nadir. Virological breakthrough values were presented from Baseline to through out the study. Baseline is defined as the value at Week 0 visit.

    Time frame: From Baseline to throughout study

  11. Number of Participants With Resistance Related Mutations at Week 24, Week 48, Week 96 and Virological Breakthrough (Baseline to Throughout the Study)

    The development of drug resistance-related (RA) mutations was analyzed to look for resistance to Lamivudine (LAM), Adefovir dipivoxil (ADV), and/or ETV in a case where a virologic breakthrough has been observed after starting the study treatment (serum HBV DNA level has increased from the nadir by at least 1 log10 copies/mL) or where the serum HBV DNA level is not less than the HBV DNA detection limit (2.1 log10 copies/mL) at Week 24, Week 48 and Week 96. Virologic breakthrough was defined as 1.0 log10 or greater increases in serum HBV-DNA levels from on-treatment nadir. Participants who achieved the HBV-DNA values below lower limit of quantification (LLQ) (\< 2.1 log10 copies/mL) in quantitative analysis at entire the study were also considered "Negative" in drug-resistance without implementation of genotypic analysis. Resistance mutation values were presented from Baseline to throughout the study. Baseline is defined as the value at Week 0 visit.

    Time frame: Screening, Week 24, Week 48, Week 96 and Virological Breakthrough (Baseline to throughout the study)

07

Results

Posted Oct 29, 2013

Participant flow

Participant flow — Overall Study
MilestoneTDF 300 mg ODETV 0.5 mg OD
Started11056
Completed10256
Not completed80
Withdrew: Withdrawal by subject20
Withdrew: Adverse event10
Withdrew: Study closed/terminated30
Withdrew: Lost to follow-up10
Withdrew: Physician decision10

Outcome measures

PrimaryMean Change From Baseline in Serum HBV DNA Level at Week 24

The mean change from Baseline in the hepatitis B virus deoxyribonucleic acid (HBV DNA) level at Week 24 was assessed (lower limit of quantitation : 2.1 log 10 copies/mL). The mean values were adjusted by Baseline HBV DNA levels. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · log10 copies/milliliter (copies/mL)
Mean Change From Baseline in Serum HBV DNA Level at Week 24
log10 copies/milliliter (copies/mL)TDF 300 mg ODETV 0.5 mg OD
Mean Change From Baseline in Serum HBV DNA Level at Week 24-4.63 ± 0.044-4.50 ± 0.063
Statistical analysis
  • TDF 300 mg OD vs ETV 0.5 mg OD · ANCOVA · p = <0.0001 (p-value was compared with the significance level of 0.025) · Mean difference (final values): -0.13 · 95% CI -0.28 to 0.02
SecondaryMean Change From Baseline in Serum HBV DNA Level at Week 48 and Week 96

The mean change from Baseline in the HBV DNA level at Week 48 and Week 96 were assessed (lower limit of quantitation : 2.1 log10 copies/mL). The mean values were adjusted by Baseline HBV DNA levels. Change from Baseline was calculated as the post-baseline value minus the Baseline value. The LOCF method was applied for missing values.

Time frame:
Baseline, Week 48 and Week 96
Reported as:
Mean · log10 copies/mL
Mean Change From Baseline in Serum HBV DNA Level at Week 48 and Week 96
log10 copies/mLTDF 300 mg ODETV 0.5 mg OD
Week 48-4.86 ± 1.353-4.85 ± 0.916
Week 96-4.96 ± 1.445NA ± NA
Statistical analysis
  • TDF 300 mg OD vs ETV 0.5 mg OD · Mean difference (final values): -0.01 · 95% CI -0.40 to 0.39CI and estimate difference is provided for change from Baseline in serum HBV DNA level at Week 48.
SecondaryNumber of Participants With Serum HBV DNA < 2.1 log10 Copies/mL at Week 24, Week 48 and Week 96

The number of participants with serum HBV DNA level less than the lower limit of quantitation (i.e. 2.1 log10 copies/mL) at Week 24, Week 48 and Week 96 were summarized. The LOCF method was applied for missing values.

Time frame:
Week 24, Week 48 and Week 96
Reported as:
Number · Participants
Number of Participants With Serum HBV DNA < 2.1 log10 Copies/mL at Week 24, Week 48 and Week 96
ParticipantsTDF 300 mg ODETV 0.5 mg OD
Week 245922
Week 488437
Week 9697NA
SecondaryNumber of Participants With Alanine Aminotransferase (ALT) Normalization at Week 24, Week 48 and Week 96

The number of participants with alanine aminotransferase (ALT) normalization at Week 24, Week 48 and Week 96 were summarized. ALT normalization is defined as when an ALT value exceeds the upper limit of normal range (ULN) at Baseline and within the normal range at the end of treatment. The LOCF method was applied for missing values.

Time frame:
Week 24, Week 48 and Week 96
Reported as:
Number · Participants
Number of Participants With Alanine Aminotransferase (ALT) Normalization at Week 24, Week 48 and Week 96
ParticipantsTDF 300 mg ODETV 0.5 mg OD
Week 245835
Week 486235
Week 9674NA
SecondaryNumber of Participants With HBeAg Loss at Week 24, Week 48 and Week 96

The number of participants achieving hepatitis Be antigen (HBeAg) loss at Week 24, Week 48 and Week 96 in positive HBeAg participants at Baseline were summarized. Loss of HBeAg is defined as the change of detectable HBeAg from positive to negative. The LOCF method was applied for missing values.

Time frame:
Week 24, Week 48 and Week 96
Reported as:
Number · Participants
Number of Participants With HBeAg Loss at Week 24, Week 48 and Week 96
ParticipantsTDF 300 mg ODETV 0.5 mg OD
Week 2432
Week 4893
Week 9613NA
SecondaryNumber of Participants With HBeAg/HBeAb Seroconversion at Week 24, Week 48 and Week 96

The number of participants achieving HBeAg/hepatitis Be antibody (HBeAb) seroconversion at Week 24, Week 48 and Week 96 in positive HBeAg and negative HBeAb participants at Baseline were summarized. Seroconversion to HBeAg is defined as the change of detectable antibody to HBeAg from negative to positive. The LOCF method was applied for missing values.

Time frame:
Week 24, Week 48 and Week 96
Reported as:
Number · Participants
Number of Participants With HBeAg/HBeAb Seroconversion at Week 24, Week 48 and Week 96
ParticipantsTDF 300 mg ODETV 0.5 mg OD
Week 2401
Week 4842
Week 965NA
SecondaryNumber of Participants Achieving HBsAg Loss at Week 24, Week 48 and Week 96

The number of participants with hepatitis B surface antigen (HBsAg) loss at Week 24, Week 48 and Week 96 in positive HBsAg participants at Baseline were summarized. Loss of HBsAg is defined as change of detectable HBsAg from positive to negative. The LOCF method was applied for missing values.

Time frame:
Week 24, Week 48 and Week 96
Reported as:
Number · Participants
Number of Participants Achieving HBsAg Loss at Week 24, Week 48 and Week 96
ParticipantsTDF 300 mg ODETV 0.5 mg OD
Week 2400
Week 4800
Week 961NA
SecondaryNumber of Participants Achieving HBsAg/HBsAb Seroconversion at Week 24, Week 48 and Week 96

The number of participants with HBsAg/hepatitis B surface antibody (HBsAb) seroconversion at Week 24, Week 48 and Week 96 in positive HBsAg and negative HBsAb participants at Baseline were summarized. HBsAg seroconversion .is defined as change of detectable antibody to HBsAg from negative to positive. The LOCF method was applied for missing values.

Time frame:
Week 24, Week 48 and Week 96
Reported as:
Number · Participants
Number of Participants Achieving HBsAg/HBsAb Seroconversion at Week 24, Week 48 and Week 96
ParticipantsTDF 300 mg ODETV 0.5 mg OD
Week 2400
Week 4800
Week 961NA
SecondaryNumber of Participants Achieving Each Indicated HBsAg Category at Baseline, Week 24, Week 48 and Week 96

The number of participants achieving each indicated HBsAg category (HBsAg \<80, 80 to 800, 800 to 8000, 8000 to 80000, and \>=80000) (kilo international unit per liter \[KIU/L\]) by study visit was summarized. The LOCF method was applied for missing values.

Time frame:
Baseline, Week 24, Week 48 and Week 96
Reported as:
Number · Participants
Number of Participants Achieving Each Indicated HBsAg Category at Baseline, Week 24, Week 48 and Week 96
ParticipantsTDF 300 mg ODETV 0.5 mg OD
HBsAg <80 KIU/L, Baseline22
HBsAg 80-800 KIU/L, Baseline1510
HBsAg 800-8000 KIU/L, Baseline5833
HBsAg 8000-80,000 KIU/L, Baseline3110
HBsAg >=80,000 KIU/L, Baseline31
HBsAg <80 KIU/L, Week 2431
HBsAg 80-800 KIU/L, Week 241710
HBsAg 800-8000 KIU/L, Week 246336
HBsAg 8000-80,000 KIU/L, Week 24269
HBsAg >=80,000 KIU/L, Week 2400
HBsAg <80 KIU/L, Week 4851
HBsAg 80-800 KIU/L, Week 48199
HBsAg 800-8000 KIU/L, Week 486039
HBsAg 8000-80,000 KIU/L, Week 48257
HBsAg >=80,000 KIU/L, Week 4800
HBsAg <80 KIU/L, Week 965NA
HBsAg 80-800 KIU/L, Week 9623NA
HBsAg 800-8000 KIU/L, Week 9660NA
HBsAg 8000-80,000 KIU/L, Week 9621NA
HBsAg >=80,000 KIU/L, Week 960NA
SecondaryNumber of Participants Achieving Each Indicated HBcrAg Category at Baseline, Week 24, Week 48 and Week 96

The number of participants achieving each indicated hepatitis B core-related antigen (HBcrAg) category (HBcrAg \<3.0, 3.0 to 4.0, 4.0 to 5.0, 5.0 to 6.0, and \>=6.0) (Log kilo unit per liter \[KU/L\]) by study visit was summarized. The LOCF method was applied for missing values.

Time frame:
Baseline, Week 24, Week 48 and Week 96
Reported as:
Number · Participants
Number of Participants Achieving Each Indicated HBcrAg Category at Baseline, Week 24, Week 48 and Week 96
ParticipantsTDF 300 mg ODETV 0.5 mg OD
HBcrAg <3.0 Log KU/L, Baseline70
HBcrAg 3.0-4.0 Log KU/L, Baseline136
HBcrAg 4.0-5.0 Log KU/L, Baseline1911
HBcrAg 5.0-6.0 Log KU/L, Baseline199
HBcrAg >=6.0 Log KU/L, Baseline5130
HBcrAg <3.0 Log KU/L, Week 242110
HBcrAg 3.0-4.0 Log KU/L, Week 24168
HBcrAg 4.0-5.0 Log KU/L, Week 24188
HBcrAg 5.0-6.0 Log KU/L, Week 24177
HBcrAg >=6.0 Log KU/L, Week 243723
HBcrAg <3.0 Log KU/L, Week 482412
HBcrAg 3.0-4.0 Log KU/L, Week 48166
HBcrAg 4.0-5.0 Log KU/L, Week 48189
HBcrAg 5.0-6.0 Log KU/L, Week 482310
HBcrAg >=6.0 Log KU/L, Week 482819
HBcrAg <3.0 Log KU/L, Week 9624NA
HBcrAg 3.0-4.0 Log KU/L, Week 9618NA
HBcrAg 4.0-5.0 Log KU/L, Week 9622NA
HBcrAg 5.0-6.0 Log KU/L, Week 9623NA
HBcrAg >=6.0 Log KU/L, Week 9622NA
SecondaryNumber of Participants With Virological Breakthrough Through End of the Study

The number of participants who experienced virological breakthrough was summarized. Virological breakthrough is defined as serum HBV DNA level increase \>=1 log10 copies/mL above the treatment nadir. Virological breakthrough values were presented from Baseline to through out the study. Baseline is defined as the value at Week 0 visit.

Time frame:
From Baseline to throughout study
Reported as:
Number · Participants
Number of Participants With Virological Breakthrough Through End of the Study
ParticipantsTDF 300 mg ODETV 0.5 mg OD
Number of Participants With Virological Breakthrough Through End of the Study22
SecondaryNumber of Participants With Resistance Related Mutations at Week 24, Week 48, Week 96 and Virological Breakthrough (Baseline to Throughout the Study)

The development of drug resistance-related (RA) mutations was analyzed to look for resistance to Lamivudine (LAM), Adefovir dipivoxil (ADV), and/or ETV in a case where a virologic breakthrough has been observed after starting the study treatment (serum HBV DNA level has increased from the nadir by at least 1 log10 copies/mL) or where the serum HBV DNA level is not less than the HBV DNA detection limit (2.1 log10 copies/mL) at Week 24, Week 48 and Week 96. Virologic breakthrough was defined as 1.0 log10 or greater increases in serum HBV-DNA levels from on-treatment nadir. Participants who achieved the HBV-DNA values below lower limit of quantification (LLQ) (\< 2.1 log10 copies/mL) in quantitative analysis at entire the study were also considered "Negative" in drug-resistance without implementation of genotypic analysis. Resistance mutation values were presented from Baseline to throughout the study. Baseline is defined as the value at Week 0 visit.

Time frame:
Screening, Week 24, Week 48, Week 96 and Virological Breakthrough (Baseline to throughout the study)
Reported as:
Number · Participants
Number of Participants With Resistance Related Mutations at Week 24, Week 48, Week 96 and Virological Breakthrough (Baseline to Throughout the Study)
ParticipantsTDF 300 mg ODETV 0.5 mg OD
LAM RA mutations, Screening, n=109, 5600
ADV RA mutations, Screening, n=109, 5600
ETV RA mutations, Screening, n=109, 5600
LAM RA mutations, Week 24, n=49, 3400
ADV RA mutations, Week 24, n=49, 3400
ETV RA mutations, Week 24, n=49, 3400
LAM RA mutations, Week 48, n=23, 1900
ADV RA mutations, Week 48, n=23, 1900
ETV RA mutations, Week 48, n=23, 1900
LAM RA mutations, Week 96, n=11, 00NA
ADV RA mutations, Week 96, n=11, 00NA
ETV RA mutations, Week 96, n=11, 00NA
LAM RA mutations, Virologic Breakthrough, n=2, 200
ADV RA mutations, Virologic Breakthrough, n=2, 200
ETV RA mutations, Virologic Breakthrough, n=2, 200

Adverse events

Collected over Serious adverse events (SAEs) and non-serious AEs were collected from the start of study medication to the end of the treatment period (up to average of 96 weeks).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
TDF 300 mg OD—7/109 (6.4%)83/109 (76.1%)
ETV 0.5 mg OD—2/56 (3.6%)40/56 (71.4%)
Most frequent serious events
Most frequent serious events
EventTDF 300 mg ODETV 0.5 mg OD
Intervertebral disc protrusionMusculoskeletal and connective tissue disorders2/1090/56
Large intestine polypGastrointestinal disorders0/1091/56
Hepatocellular carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/1091/56
ArrhythmiaCardiac disorders1/1090/56
Food poisoningGastrointestinal disorders1/1090/56
Urinary tract infectionInfections and infestations1/1090/56
DizzinessNervous system disorders1/1090/56
Multiple fracturesInjury, poisoning and procedural complications1/1090/56
Ovarian germ cell teratoma benignNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/1090/56
Most frequent other events
Showing 10 of 18
Most frequent other events
EventTDF 300 mg ODETV 0.5 mg OD
NasopharyngitisInfections and infestations48/10924/56
HeadacheNervous system disorders16/1095/56
Blood creatine phosphokinase increasedInvestigations11/1094/56
InfluenzaInfections and infestations10/1093/56
PharyngitisInfections and infestations10/1092/56
RashSkin and subcutaneous tissue disorders2/1095/56
Abdominal pain upperGastrointestinal disorders8/1090/56
Dental cariesGastrointestinal disorders4/1094/56
Back painMusculoskeletal and connective tissue disorders6/1094/56
SinusitisInfections and infestations7/1093/56

Baseline characteristics

Age, Continuous
Age, Continuous(Years)TDF 300 mg ODETV 0.5 mg ODTotal
Mean45.4 ± 9.2346.1 ± 9.6845.6 ± 9.36
Sex: Female, Male
Sex: Female, Male(Participants)TDF 300 mg ODETV 0.5 mg ODTotal
Female411657
Male6840108
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)TDF 300 mg ODETV 0.5 mg ODTotal
Asian - Japanese Heritage10956165
08

Study locations

32 sites
  • GSK Investigational Site
    Aichi, 466-8560, Japan
  • GSK Investigational Site
    Aichi, 467-8602, Japan
  • GSK Investigational Site
    Chiba, 260-8677, Japan
  • GSK Investigational Site
    Fukui, 918-8503, Japan
  • GSK Investigational Site
    Fukuoka, 803-8505, Japan
  • GSK Investigational Site
    Fukuoka, 810-8539, Japan
  • GSK Investigational Site
    Fukuoka, 812-8582, Japan
  • GSK Investigational Site
    Fukuoka, 820-8505, Japan
  • GSK Investigational Site
    Gifu, 500-8717, Japan
  • GSK Investigational Site
    Hiroshima, 734-8530, Japan
  • GSK Investigational Site
    Hyogo, 651-2273, Japan
  • GSK Investigational Site
    Hyogo, 663-8501, Japan
  • GSK Investigational Site
    Kagawa, 760-8557, Japan
  • GSK Investigational Site
    Kagoshima, 890-8520, Japan
  • GSK Investigational Site
    Kagoshima, 892-8512, Japan
  • GSK Investigational Site
    Kanagawa, 213-8587, Japan
  • GSK Investigational Site
    Kumamoto, 862-8655, Japan
  • GSK Investigational Site
    Miyagi, 980-8574, Japan
  • GSK Investigational Site
    Miyazaki, 880-0003, Japan
  • GSK Investigational Site
    Nagasaki, 852-8501, Japan
  • GSK Investigational Site
    Nagasaki, 856-8562, Japan
  • GSK Investigational Site
    Nara, 630-8305, Japan
  • GSK Investigational Site
    Okayama, 700-0913, Japan
  • GSK Investigational Site
    Okayama, 700-8511, Japan
  • GSK Investigational Site
    Osaka, 540-0006, Japan
  • GSK Investigational Site
    Osaka, 564-0013, Japan
  • GSK Investigational Site
    Saga, 840-8571, Japan
  • GSK Investigational Site
    Tokyo, 105-8470, Japan
  • GSK Investigational Site
    Tokyo, 105-8471, Japan
  • GSK Investigational Site
    Tokyo, 140-8522, Japan
  • GSK Investigational Site
    Tokyo, 162-8655, Japan
  • GSK Investigational Site
    Tokyo, 180-8610, Japan
09

References and documents

Publications

  • Koike K, Suyama K, Ito H, Itoh H, Sugiura W. Randomized prospective study showing the non-inferiority of tenofovir to entecavir in treatment-naive chronic hepatitis B patients. Hepatol Res. 2018 Jan;48(1):59-68. doi: 10.1111/hepr.12902. Epub 2017 May 24. PubMed 28374496 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2011, a primary completion of Jan 2013 and a completion of Nov 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2013, 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 23, 2011
First posted
Nov 28, 2011
Start
Nov 2011
Primary completionActual
Jan 2013
CompletionActual
Nov 2014
Results first posted
Oct 29, 2013
Last update
Aug 10, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 10, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01480284
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Nov 28, 2011
Start date
Nov 2011
Primary completion
Jan 2013
Completion
Nov 2014
Results posted
Oct 29, 2013
Last update
Aug 10, 2016

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tenofovir

Start the discussion